Indegene Limited has informed the Exchange about Investor Presentation
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indegene Limited filed its investor presentation ahead of an analyst meet. The company reported FY26 revenue of INR 35.1 billion with 19.4% adjusted EBITDA margin and 162% OCF-to-PAT ratio. Key metrics include 29.4% revenue CAGR over FY21-FY26, revenue per employee of $74.7K, and net revenue retention above 100% for every year. The company serves 20 of Top 20 and 80 of Top 100 global life sciences companies. Client base grew from 44 to 91 active clients, with top-20 client revenue expanding 3x over five years. For FY27, the pipeline is 17% higher than the prior year with balanced strength across client cohorts. Indegene positions itself as an AI-embedded operating partner for life sciences, competing against traditional agencies and CROs with a $2B+ growth vision targeting enterprise clients.
The presentation signals strong execution with consistent margin, cash generation, and client expansion. The 17% higher pipeline entering FY27 and multi-year tier migration targets provide revenue visibility. The company is pursuing aggressive share gains from fragmented agencies and CROs in a $54B-$100B outsourced life sciences market, with zero debt providing financial flexibility for growth investments.